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The oligomeric lipid raft-associated integral protein
stomatin normally localizes to the plasma membrane
and the late endosomal compartment. Similar to the
caveolins, it is targeted to lipid bodies (LBs) on overex-
pression. Endogenous stomatin also associates with LBs
to a small extent. Green fluorescent protein-tagged sto-
matin (StomGFP) and the dominant-negative caveolin-3
mutant DGV(cav3)HA occupy distinct domains on LB
surfaces but eventually intermix. Studies of StomGFP
deletion mutants reveal that the region for membrane
association but not oligomerization and raft association
is essential for LB targeting. Blocking protein synthesis
leads to the redistribution of StomGFP from LBs to Ly-
soTracker-positive vesicles indicating a connection
with the late endosomal/lysosomal pathway. Live mi-
croscopy of StomGFP reveals multiple interactions be-
tween LBs and microtubule-associated vesicles possibly
representing signaling events and/or the exchange of
cargo. Proteomic analysis of isolated LBs identifies adi-
pophilin and TIP47, various lipid-specific enzymes, cy-
toskeletal components, chaperones, Ras-related pro-
teins, protein kinase D2, and other regulatory proteins.
The association of the Rab proteins 1, 6, 7, 10, and 18
with LBs indicates various connections to other com-
partments. Our data suggest that LBs are not only in-
volved in the storage of lipids but also participate ac-
tively in the cellular signaling network and the
homeostasis of lipids.
The 31-kDa integral protein stomatin, a major protein of the
erythrocyte membrane (1–3), is widely expressed in vertebrate
tissues and cell lines of myeloid, endothelial, and epithelial
origin. It shares some topological and biochemical properties
with the caveolins (4, 5), notably a large hydrophobic domain
that may anchor the protein to the cytoplasmic leaflet of the
lipid bilayer (6) and palmitoylation sites (7). Likewise, stomatin
is organized in high order oligomers and associates with lipid
rafts (7, 8), thereby suggesting a scaffolding function. In epi-
thelial UAC cells, stomatin is found in two different pools, the
plasma membrane and lysosomal-associated membrane pro-
tein 2-positive, perinuclear vesicles representing late endo-
somes or lysosomes. In both compartments, stomatin co-local-
izes with two lipid raft-resident glycosylphosphatidylinositol-
anchored proteins. Co-patching of stomatin with cross-linked
placental alkaline phosphatase indicates an interaction of
these proteins via the membrane microdomains. In Madin-
Darby canine kidney (MDCK)1 cells, the subcellular localiza-
tion of stomatin redistributes from perinuclear vesicles to the
apical membrane upon polarization (8). In hematopoietic cells,
stomatin is identified in rafts of the plasma membrane and
granular membranes (9, 10).
Recent studies have shown that caveolin family members
can associate with cytoplasmic lipid bodies (LBs), also known
as lipid (storage) droplets, lipid globules, or lipid particles.
Overexpression of caveolin-1, -2, and -3 leads to the targeting of
these proteins to LBs that is enhanced by the treatment of the
cells with brefeldin A (BFA) and/or oleic acid (11–13). Caveo-
lin-1 (cav1) fused to an endoplasmic reticulum (ER)-retrieval
signal is highly concentrated in LBs, and a cav1-mutant is
targeted to LBs and the Golgi complex. Moreover, treatment
with BFA causes the accumulation of endogenous cav1 in LBs
(12). Likewise, LB association of endogenous cav2 in fibroblasts
is accelerated by oleic acid/BFA treatment. Studies with cav2
deletion mutants reveal that the central hydrophobic domain
and the adjacent N- and C-terminal hydrophilic domains are
necessary for LB targeting of this protein (11). The N-terminal
deletion mutant of caveolin-3 specifically associates with LBs.
Expression of this dominant-negative mutant causes intracel-
lular accumulation of free cholesterol in late endosomes, a
decrease in surface cholesterol, and a decrease in cholesterol
efflux and synthesis (13). In addition, recent studies have
shown that endogenous caveolin is associated with LBs in
cultured cells treated with fatty acids and in regenerating
liver (14).
LBs are found in most eukaryotic cells and play a role in the
storage and turnover of neutral lipids, notably triacylglycerol,
cholesteryl ester, and retinyl ester, depending on the cell type
(15–18). They are thought to originate from the membrane of
the ER with newly synthesized neutral lipids being inserted
between the bilayer causing the cytoplasmic leaflet to bulge
and eventually bud off into the cytoplasm. LBs are surrounded
by a phospholipid monolayer that has a composition different
from the ER membrane or rafts (19). Major mammalian LB
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proteins identified to date are members of the PAT protein
family (the perilipins, adipose differentiation-related protein
(ADRP), also termed adipophilin, and TIP47) (20, 21). Whereas
perilipins are restricted to adipose and steroidogenic cells,
ADRP is widely expressed in various cell types (22–25). ADRP
has been suggested to act as a transporter for fatty acids from
the plasma membrane or cytosol to the surface of LBs (26, 27),
whereas perilipins are thought to sterically block the access of
hormone-sensitive lipase to the lipids, consequently preventing
triacylglycerol hydrolysis (28–30).
The topological and biochemical similarity of stomatin and
the caveolins prompted us to investigate the subcellular distri-
bution of stomatin in response to intracellular LB accumula-
tion. Here we show that stomatin associates with LBs when
exogenously expressed at high levels or endogenously in the
presence of oleic acid. Blocking vesicular transport with BFA
leads to an increased association of endogenous stomatin with
LBs, in accordance with the current hypothesis of LB forma-
tion. Cycloheximide treatment results in the dissociation of
stomatin from LBs and appearance on acidic vesicles. Live
microscopy reveals that stomatin-positive LBs are dynamic
structures interacting with small vesicles and occasionally
showing high motility. To gain insight into LB function, we
performed a proteomic study of LB proteins from the human
A431 cell line and report here the identification of 33 LB
proteins, most notably Rab GTPases, lipid metabolic enzymes,
and transport-associated proteins.
EXPERIMENTAL PROCEDURES
Reagents—Aprotinin, brefeldin A, cycloheximide, fatty acid-free bo-
vine serum albumin (BSA), leupeptin, Nile red, nocodazole, oleic acid,
pepstatin a, and phenylmethylsulfonyl fluoride were from Sigma.
Tween 20 was from Merck, and reinforced nitrocellulose OPTI-TRAN
BA-S 83 was from Schleicher & Schuell.
Antibodies—The mouse monoclonal antibody against stomatin
(GARP-50) has been described (1, 31), and monoclonal antibody against
adipophilin was obtained from Research Diagnostics (Flanders, NJ).
Other monoclonal antibodies used in this study were anti--tubulin
(Sigma), anti-c-Myc (clone 9E10) (Roche Applied Science), anti-GM130
(BD Transduction Laboratories), anti-transferrin receptor (Santa Cruz
FIG. 1. High expression of stomatin
in oleic acid-treated cells results in
LB association. A, MDCK cells were
treated with oleic acid for 24 h and
stained with anti-stomatin (green) and
Nile red (LB staining). Endogenous sto-
matin localizes to the perinuclear region
but is not detected on LBs. (B and C)
MDCK cells transiently expressing
StomGFP (B) or human WT stomatin (C)
were treated with oleic acid for 24 h and
stained with Nile red. WT stomatin was
immunostained. Overexpression of sto-
matin, either tagged or untagged, results
in LB association. Arrows indicate
StomGFP- or stomatin-positive vesicles,
respectively. D and E, LBs from oleic acid-
treated MDCK cells stably expressing
StomGFP were isolated by discontinuous
density gradient centrifugation. D, West-
ern blot analysis of the density gradient
fractions. The majority of StomGFP is
found in fraction 1 containing the LBs.
This is confirmed by the exclusive pres-
ence of the LB marker adipophilin. E, flu-
orescence microscopy of isolated and Nile
red-stained LBs shows the same ring-like
structures as in fixed MDCK cells. This
indicates a tight association of StomGFP
with LBs. The inset shows a 3-fold mag-
nification of one LB exhibiting a thick-
ened area of StomGFP (inset, arrowhead).
Bars  10 m (A–C) and 2 m (E).
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Biotechnology, Inc.), anti-KDEL receptor (Stressgen), and anti-COX IV
(Molecular Probes, Leiden, Holland). Rabbit anti-HA antibody was from
Santa Cruz Biotechnology. Alexa-conjugated secondary antibodies were
obtained from Molecular Probes.
Cell Culture—Human epithelial cells of amniotic origin (UAC) (31),
human squamous epithelial carcinoma cells (A431), and MDCK epithe-
lial cells, strain II, were maintained in Dulbecco’s modified Eagles
medium (DMEM, Invitrogen) supplemented with 10% fetal calf serum
(Invitrogen) and antibiotics (100 units/ml penicillin and streptomycin)
under standard conditions.
Vector Construction and Transfection—pCB6-DGVHA was described
previously (32). To express human wild-type (WT) stomatin, the eu-
karyotic expression vector pEF-Puro.PL3 was used as described previ-
ously (33). The cDNA coding for human WT stomatin was generated by
PCR and was directionally cloned into the unique restriction
sites SpeI/EcoRV.
To express GFP-tagged stomatin and variants, cDNAs, which code
for human WT or truncated stomatin extended by an alanine-linker
(Gly-Ala-Ala-Ala) at the C terminus, were generated by PCR using the
primers ST1Kozak.EcoRI, 5-TACGGAATTCCGCCACCATGGCCGAG-
AAGCGGCACACAC-3; ST287Ala.BamHI, 5-TGCGGGATCCGGCGG-
CAGCGGCTCCGCCTAGATGGCTGTGTTTTGCC-3; ST21Kozak.
EcoRI, 5-TACGGAATTCCGCCACCATGAGCCCCAGTAAGGGCCTT-
GGAC-3; and ST262Ala.BamHI, 5-TGCGGGATCCGGCGGCAGCGG-
CTCCTTTCTCAGCAGCAATGGTGGTC-3. cDNAs were directionally
cloned into the unique restriction sites EcoRI/BamHI of pEGFP-N3,
resulting in a translated protein stomatin(mutant)-Gly-Ala-Ala-Ala-
GFP. To express Myc-tagged flotillin-2, the cDNA coding for rat WT
flotillin-2 was generated by PCR using the primers 1ratFlot2.KpnI,
5-CGGGGTACCATGGGCAATTGCCACACGGTG-3, and EndratFlot-
2.KpnI, 5-CGGGGTACCCACCTGCGCACCAGTGGCATTC-3. The
cDNA was cloned into the unique restriction site KpnI of pEFKMyc
(7, 33). All of the constructs were checked by dideoxy sequencing.
MDCK or A431 cells were stably or transiently transfected using
MetafecteneTM (Biontex) or Calcium Phosphate (Promega). After se-
lection in medium containing 2 g/ml puromycin and/or 70 g/ml
G418, individual stable clones were picked by trypsinization using
cloning rings. Expression of the recombinant protein was screened by
Western blot analysis using anti-Myc or anti-stomatin antibody.
GFP-expressing clones were screened by fluorescence microscopy.
The double transfectants (MDCKII/StomGFP/DGV(cav3)HA) were an-
alyzed by indirect immunofluorescence microscopy using the anti-HA
antibody.
Isolation of Lipid Bodies—Cells were grown on 15-cm dishes in
DMEM/fetal calf serum until 2 days before confluency. At this stage, the
medium was supplemented with 0.4 mM oleic acid, 66.7 M fatty acid-
free BSA (22) and the cells were grown for two more days. The cells were
rinsed twice with phosphate-buffered saline, and 4.5 ml of TNE buffer
(20 mM Tris-Cl, pH 8.0, 130 mM NaCl, 5 mM EDTA) containing protease
inhibitors (10 g/ml aprotinin and leupeptin, 1 g/ml pepstatin a, and
1 mM phenylmethylsulfonyl fluoride) were added per dish. The cells
were scraped off and disrupted in a Dounce homogenizer on ice. Lipid
bodies were isolated essentially as described previously (34). The cell
lysate was adjusted to 0.43 M sucrose in TNE. After centrifugation at
1500  g for 10 min (2800 rpm, HB-4, Sorvall) to pellet nuclei and
unbroken cells, the supernatant was transferred to a 13-ml ultracen-
trifuge tube (Ultraclear 14  95 mm, Beckman) and overlaid sequen-
tially with 2.0 ml of 0.27 M sucrose/TNE, 0.135 M sucrose/TNE, and
TNE, respectively. After centrifugation at 150,000  g for 60 min
(SW40, 29 000 rpm, Beckman), 18 fractions of 670 l each were col-
lected from above. Lipid bodies floated as a thin white film on top of the
gradient and were resuspended in a volume of 200 l. Isolated LBs were
either solubilized in SDS-containing sample buffer for subsequent SDS-
PAGE or resuspended in TNE for subsequent Nile red staining and
fluorescence microscopy.
Western Blot Analysis—Fractions collected from the sucrose gradi-
ents were analyzed by 10% SDS-PAGE and electrotransferred to nitro-
FIG. 2. Targeting of endogenous
stomatin to LBs analyzed by Western
blotting. LBs from oleic acid-treated
UAC cells endogenously expressing sto-
matin were isolated by discontinuous
density gradient centrifugation, and 50%
of fraction 1 (LB fraction) and 3% of frac-
tions 2–19 were subjected to SDS-PAGE.
Western blot analysis of the density gra-
dient fractions shows that the markers for
the Golgi complex, GM130, for mitochon-
dria, COX IV, and for the plasma mem-
brane, transferrin receptor, are excluded
from the LB fraction, whereas a small
part of the ER marker KDEL receptor is
found in this fraction.
FIG. 3. Targeting of endogenous stomatin to LBs by accumu-
lation in the ER. A–C, UAC cells endogenously expressing stomatin
were either treated with BFA (B) or BFA/oleic acid (C) or left untreated
(A). Stomatin was immunostained, and LBs were stained with Nile red.
In contrast to untreated cells (A), BFA-treated cells show the formation
of small structures stained with anti-stomatin (green) on the surface
and Nile red in the center (arrows) (B). When UAC cells are grown in
the presence of oleic acid and BFA, the LB targeting of endogenous
stomatin is dramatically enhanced (C). This association is stable during
the subsequent washout of BFA for at least 17 h (D). Bars  5 m (A
and B) and 10 m (C and D).
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cellulose by standard methods as described previously (8). HighPreci-
sionProteinTM Standards (Bio-Rad) were used as molecular weight
markers. After blocking, the blots were incubated with mouse anti-
stomatin antibody GARP50 (diluted 1/15 in Tris-buffered saline, pH 8,
0.1% BSA), mouse anti-GM130 (diluted 1:250), mouse anti-KDEL re-
ceptor (diluted 1:250), rabbit anti-transferrin receptor (diluted 1:200),
or with mouse anti-ADRP (diluted 1:200) for 1 h with the exception of
the mouse anti-COX IV (1.4 g/ml) that was incubated overnight. After
a final wash, the blots were incubated with anti-mouse or anti-rabbit
horseradish peroxidase conjugate (Pierce). Visualization of signals was
performed using SuperSignal chemiluminescent substrate (Pierce).
Confocal Fluorescence Microscopy—MDCK, A431 cells, and UAC
cells, transfected or untransfected, were grown in medium with or
without 0.4 mM oleic acid, 66.7 M fatty acid-free BSA overnight. BFA
treatment was performed at 10 g/ml BFA in DMEM/fetal calf serum
medium for 5 h. Cycloheximide was used at 2 g/ml in medium for up
to 24 h. Immunofluorescence with anti-stomatin, anti-Myc, or an-
ti-HA antibody was essentially performed as described previously (31,
33) with the exception that fixed and permeabilized cells were incu-
bated with the HA antibody overnight. For co-staining of LBs, the
fixed cells were first immunostained and subsequently incubated
with a diluted solution of Nile red (1/1000 (v/v) in phosphate-buffered
saline) from a saturated solution in acetone and mounted (Vectash-
ield, Vector Laboratories). Isolated LBs containing StomGFP were
stained by incubation with Nile red at a final dilution of 1/200 for 10
min and were mounted immediately. LysoTracker (Molecular Probes)
staining was performed by incubating cells with 15 nM of this dye in
DMEM at 37 °C for 30 min and chasing with DMEM at 37 °C for 40
min prior to fixing. Pictures were taken using a confocal microscope
(TCSNT, Leica) and the corresponding software. Nile red staining
was detected in the TRITC channel, and the signal was quenched for
30 s before pictures in the fluorescein isothiocyanate channel were
taken.
Time Lapse Video Microscopy—MDCK cells stably transfected with
StomGFP were grown on coverslips for 1 day in DMEM, 10% fetal calf
serum and subjected to live cell microscopy in the presence of DMEM.
The setup consisted of a Zeiss Axiovert 200 microscope with a Zeiss
Plan-Apochromat 100 objective lens and a nitrogen-cooled back-
illuminated camera (Roper Scientific). Fluorescence was excited at
488 nm with an Argon ion laser (Spectra Physics) using a power of 7
watts/cm2. A stack of six planes in the z axis was recorded and
digitalized every 490 ms. Exposure time per plane was 10 ms, and the
time between two planes was 10 ms. The videos are shown at 5-fold
speed.
Proteomic Analysis of Isolated Lipid Bodies—Isolated LBs were dis-
solved in sample buffer, separated by SDS-PAGE, and silver-stained
(35). The major bands were excised and in-gel digested as de-
scribed previously (36). The peptide-mapping experiments were carried
out with a Bruker REFLEX III (Bruker Daltonik GmbH, Bremen,
Germany) matrix-assisted laser desorption/ionization time-of-flight
(MALDI-TOF) mass spectrometer equipped with a standard nitrogen
laser (337 nm). The spectra were recorded in reflectron mode, positive
ionization, and with 25-kV acceleration voltage. The laser power was
varied on a relative scale of 0–100 and was kept at the threshold value
to obtain appropriate signal intensity. The calibration of the instrument
was done externally with the peptide mixture supplied by Bruker (part
number 206195). The mass spectrometry samples were prepared with a
75:25 (v/v) mixture of the -cyano-4-hydroxycinnamic acid matrix (sat-
urated solution in acetone) and nitrocellulose (10 mg/ml in acetone-
isopropyl alcohol, 50:50 v/v). 1 l of this solution was placed onto the
polished steel sample slide and dried at room temperature. 0.5 l of the
in-gel digest was mixed with 0.5 l of 0.1% trifluoroacetic acid on this
thin layer of matrix crystals, and the spots were vacuum-dried and
washed with 0.1% trifluoroacetic acid. Each mass spectrum was pro-
duced by accumulating data from 50 to 100 consecutive laser shots.
Monoisotopic mass values are reported through the results.
RESULTS
Highly Expressed Stomatin Is Targeted to Lipid Bodies—
When MDCK cells are grown under normal cell culture condi-
tions, endogenous stomatin is mainly targeted to perinuclear
vesicles as demonstrated previously (8). To induce the accumu-
lation of LBs, MDCK cells were grown in medium supple-
mented with oleic acid. Subsequent immunofluorescence mi-
croscopy shows that endogenous stomatin does not associate
with the Nile red-stained LBs but concentrates in perinuclear
vesicles similar to the distribution in untreated cells (Fig. 1A).
In contrast, when stomatin is transiently overexpressed in
untreated MDCK cells as a GFP fusion protein (StomGFP), half
of the transfected cells show few small rings of StomGFP, the
FIG. 4. N-terminal or C-terminal
truncated versions of stomatin asso-
ciate with LBs. MDCK cells transiently
expressing GFP-tagged truncated mu-
tants were treated with oleic acid for 17 h
and stained with Nile red. A, the C-termi-
nally truncated form of stomatin, ST(1–
262)GFP, associates with LBs despite its
inability to form high order oligomers and
its absence from lipid rafts. B, ST(21–
287)GFP, an oligomeric and raft-associ-
ated N-terminal truncation version, is
also observed on the surface of LBs.
Bars  10 m (A and B). C, schematic
drawing of GFP- or Myc-tagged proteins
used in this study. The red bar indicates the
putative membrane-anchoring domain.
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interior of which is stained with Nile red (not shown). Treat-
ment of these transfected MDCK cells with oleic acid results in
the formation of large spherical and oval-shaped LBs sur-
rounded by StomGFP in almost every cell (Fig. 1B), whereas
transiently expressed enhanced GFP shows a diffuse distribu-
tion throughout the cytoplasm and is excluded from LBs (not
shown). In addition to the observed LB association, StomGFP is
found on small cytoplasmic vesicles (Fig. 1B, arrows). Un-
tagged WT stomatin transiently overexpressed in MDCK cells
is also associated with few small LBs in roughly one-third of
the transfected cells (not shown), whereas in oleic acid-treated
MDCK cells, it associates effectively with large Nile red-posi-
tive LBs in three quarters of the transfected cells (Fig. 1C). The
WT stomatin is also detected on cytoplasmic vesicles (Fig. 1C,
arrows), consistent with our previous findings.
To characterize the stomatin-positive LBs in more detail, we
isolated LBs from oleic acid-treated MDCK cells stably express-
ing StomGFP by discontinuous density gradient ultracentrifu-
gation and analyzed the gradient fractions by Western blotting.
Fig. 1D shows that the major part of StomGFP is associated
with LBs. The LB marker adipophilin is found exclusively in
the LB fraction (Fig. 1D). To demonstrate that the ring-like
fluorescence pattern of StomGFP in fixed MDCK cells is not the
result of simple displacement by LBs, we stained isolated LBs
with Nile red and subjected them to confocal microscopy. Fig.
1E clearly shows the association of StomGFP with the LB
surface. Interestingly, some rings exhibit thickened areas of
fluorescence (Fig. 1E, inset, arrowhead) that may be function-
ally relevant.
A Small Fraction of Endogenous Stomatin Associates with
LBs—To analyze LBs by Western blotting for the presence of
endogenous stomatin, UAC cells were grown in medium sup-
plemented with oleic acid and LBs were isolated by density
gradient centrifugation. Aliquots of the gradient fractions were
analyzed using antibodies against stomatin and various
marker proteins as indicated (Fig. 2). A small amount of en-
dogenous stomatin is found in the LB fraction along with the
LB marker ADRP/adipophilin. The marker proteins for the
Golgi complex, mitochondria, and the plasma membrane are
not present in the LB fraction, whereas a small part of the ER
marker KDEL receptor is found in this fraction. This finding
can be explained by a partial physical interaction of LBs with
the ER membrane as previously shown (13).
Brefeldin A Treatment Leads to the Accumulation of Endog-
enous Stomatin in the ER and Targets the Protein to LBs—To
confirm the hypothesis that accumulation of stomatin in the
ER membrane causes its association with LBs, we increased
the concentration of endogenous stomatin in the ER by treat-
ment with BFA. Because of the resulting collapse of the Golgi
complex into the ER (37), the newly synthesized endogenous
stomatin should accumulate in the ER membrane Therefore,
we investigated the LB association of endogenous stomatin in
untreated and BFA-treated UAC cells. In comparison to un-
treated cells that do not show stomatin-positive ring-like struc-
tures (Fig. 3A), BFA-treated cells exhibit stomatin labeling on
the surface of small vesicular structures that are also stained
with Nile red and therefore represent small LBs (Fig. 3B,
arrows). When UAC cells are grown in the presence of oleic acid
and BFA, the LB targeting of endogenous stomatin is dramat-
ically enhanced (Fig. 3C). This association is stable for at least
17 h during the subsequent washout of BFA (Fig. 3D).
Oligomerization, Lipid Raft Association and the N-terminal
Domain of Stomatin Are Not Prerequisites for the Association
with LBs—We have previously shown that stomatin forms high
order oligomers that are soluble in Triton X-100 at room tem-
perature (33) and demonstrated that the tagged C-terminally
truncated form of stomatin (amino acids 1–262), ST262Myc5, is
not incorporated into these oligomers and is excluded from lipid
rafts (8). Therefore, we were interested to investigate the LB
association of this variant in response to oleic acid treatment.
MDCK cells transiently expressing ST(1–262)GFP, the respec-
tive GFP fusion protein, for 48 h were grown for 17 h in a
medium containing oleic acid. The cells were fixed and stained
with Nile red. Clearly, ST(1–262)GFP associates with LBs (Fig.
4A) despite its inability to form oligomers and associate with
rafts.
Deletion of the N-terminal 20 amino acids of stomatin does
not affect the incorporation into oligomers or association with
rafts.2 We also investigated the LB association of this variant,
ST(21–287)GFP. MDCK cells transiently expressing this pro-
tein were treated with oleic acid and subjected to confocal
microscopy. As shown in Fig. 4B, ST(21–287)GFP is also ob-
served on the surface of LBs. However, the deletion of the large
2 E. Umlauf, unpublished data.
FIG. 5. Subcellular localization of StomGFP, DGV(cav3)HA, and
Flot2-Myc in oleic acid-treated MDCK cells. A and B, MDCK cells
stably expressing StomGFP and DGV(cav3)HA were treated with oleic
acid for 17 h and stained with anti-HA (red). A, StomGFP (arrows) and
DGV(cav3)HA (arrowheads) form separate ring-like structures that
show mutually excluded protein staining. The staining appears discon-
tinuous and punctated. B, StomGFP and DGV(cav3)HA co-localize com-
pletely on the surface of LBs. C, MDCK cells stably expressing
StomGFP and transiently expressing DGV(cav3)HA were incubated
with oleic acid for 19 h and stained with anti-HA. StomGFP and
DGV(cav3)HA associate with the same LBs but do not co-localize (ar-
rowheads). D, MDCK cells stably expressing StomGFP and transiently
expressing rat Flot2-Myc were treated with oleic acid for 24 h and
stained with anti-Myc. In contrast to StomGFP, Flot2-Myc is excluded
from LBs and localizes to the plasma membrane. Bars  10 m (A–D).
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hydrophobic domain, as in ST(88–287)Myc, does not allow LB
association but results in cytoplasmic expression (data not
shown).
StomGFP and DGV(cav3)HA Associate with Distinct or the
Same LBs, Whereas Flot2-Myc Is Excluded from LBs—To study
whether stomatin and the dominant-negative caveolin-3 mu-
tant that is irreversibly accumulating in LBs would associate
with the same or different LBs, we stably co-expressed
StomGFP and the HA-tagged N-terminal truncation mutant
DGV(cav3)HA in MDCK cells and treated these cells with oleic
acid. In nine independent experiments, we found that 10% of
these cells show StomGFP and DGV(cav3)HA association with
different LBs, often in a discontinuous and punctated manner
rather than forming full rings (compare arrows and arrow-
heads in Fig. 5A). Most of the cells (85%) show the targeting of
both proteins to the same LBs and co-localization in all of the
ring-like structures (Fig. 5B). Notably, in 5% of the cells when
oleic acid-treated MDCK cells stably express StomGFP and
transiently express DGV(cav3)HA, we observed a striking stain-
ing pattern. Single LBs of these cells express both proteins in
distinct domains (Fig. 5C, arrowheads) complementing each
other to form ring-like structures.
To analyze whether stomatin and a related flotillin/reggie
protein would co-localize, we used MDCK cells stably express-
ing StomGFP and transiently expressing C-terminally Myc-
tagged rat flotillin-2/reggie-1 (Flot2-Myc) and treated these
cells with oleic acid. We observed that StomGFP associates
with LBs but Flot2-Myc is excluded from these structures and
localizes to the plasma membrane (Fig. 5D).
Blocking of Protein Synthesis Results in Redistribution of
StomGFP and DGV(cav3)HA from LBs to Vesicles—To study
the turnover of LB-associated StomGFP and DGV(cav3)HA,
MDCK cells stably expressing these proteins were grown in a
medium containing oleic acid and then treated with cyclohex-
imide for an additional 24 h. The cells were labeled with an-
ti-HA prior to staining with Nile red. As shown in Fig. 6A, both
proteins, StomGFP and DGV(cav3)HA, accumulate in different
vesicular structures that are not stained with Nile red (com-
pare arrows and arrowheads). StomGFP concentrates in small
vesicles of the perinuclear region similar to endogenous stoma-
tin in oleic acid-treated MDCK cells (Fig. 1A), whereas
DGV(cav3)HA is found in larger vesicles near the periphery.
Interestingly, these vesicle populations do not co-localize, im-
plicating that both proteins are specifically targeted to differ-
ent membranes and thereby segregate.
To examine the nature of the perinuclear vesicles labeled by
StomGFP, MDCK cells stably expressing StomGFP were
treated with oleic acid followed by cycloheximide prior to fixa-
tion and Nile red staining. Again, the blocking of protein syn-
thesis causes the redistribution of StomGFP from the LBs to
the perinuclear vesicles, whereas the LBs are detected near the
periphery (Fig. 6B). When these cells are treated with Lyso-
Tracker, the centers of the StomGFP-positive perinuclear ves-
icles are stained, indicating that these structures belong to the
endosomal/lysosomal pathway (Fig. 6C). These observations
are consistent with our previous findings that stomatin-con-
taining vesicles present in the cytoplasm of UAC cells are
largely lysosomal-associated membrane protein 2-positive en-
dosomes or lysosomes (8).
Interaction between StomGFP-positive LBs and Vesicles—In
MDCK cells stably expressing StomGFP or WT stomatin, we
observed the labeling of LBs and cytoplasmic vesicles (Fig. 1, B
and C). This raised the question of whether a pathway exists
between these compartments. Because cytoplasmic vesicles
move along microtubules, we studied the localization of the
StomGFP-positive LBs and vesicles in the presence or absence
of the tubulin-binding drug nocodazole. MDCK cells stably
expressing StomGFP were treated with oleic acid for 24 h.
FIG. 6. Blocking of protein synthesis results in redistribution of StomGFP and DGV(cav3)HA from LBs to different vesicular
structures. A, MDCK cells stably expressing StomGFP and DGV(cav3)HA were treated with oleic acid for 24 h. Subsequently, protein synthesis
was blocked with cycloheximide for 24 h and cells were stained with anti-HA and Nile red. StomGFP (green, arrows) and DGV(cav3)HA (blue,
arrowheads) are not associated with LBs any more but segregate to different vesicular structures that are Nile red-negative. B, MDCK cells stably
expressing StomGFP were treated with oleic acid for 12 h followed by incubation with cycloheximide for an additional 24 h and staining with Nile
red. StomGFP is largely not present on LBs anymore but associates with vesicular structures in the perinuclear region, whereas LBs are found
in the periphery. This staining pattern resembles that of endogenous stomatin in oleic acid-treated MDCK cells (see Fig. 1A). C, MDCK cells stably
expressing StomGFP were treated as in B with the exception that cells were stained with LysoTracker instead of Nile red. StomGFP is found in
the perinuclear region on the surface of acidic LysoTracker-positive vesicles (arrows). Bars  10 m (A–C).
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Subsequently, oleic acid was removed and the cells were grown
in normal medium or medium containing nocodazole and pro-
cessed for indirect immunofluorescence with anti-tubulin. Ap-
parently, the subcellular localization of LBs is unaffected by
the disruption of the microtubules (Fig. 7, compare A with B).
As shown before (in Fig. 1E), thickened areas of StomGFP
labeling in the LB rings were observed (Fig. 7A, arrowheads)
and some rings showed spike-like protrusions (Fig. 7A, inset,
arrow). Individual StomGFP-positive vesicles were detected in
untreated cells but could not be assigned to single microtubules
because of the density of the network (Fig. 7A, arrows). Treat-
ment with nocodazole results in a diffuse cytoplasmic tubulin
staining and the StomGFP-positive vesicles form aggregates,
indicating their association with the microtubular network
(Fig. 7, compare A with B, arrows). In contrast, disruption of
the actin filaments by cytochalasin D treatment had no effect
on vesicle motility (data not shown).
Live microscopy of MDCK cells stably expressing StomGFP
reveals multiple interactions between LBs and vesicles (Fig. 7,
C–E, Videos 1–3). The StomGFP-positive vesicles are showing
fast bidirectional movement (average1.3 m/s) with interme-
diate stop-and-go phases indicating their association with mi-
crotubules. Treatment with nocodazole completely abolishes
this vesicle motility (data not shown). StomGFP-positive LBs
show little mobility in their clustered form; however, occasion-
ally a single LB is released from a cluster and moves with
relatively high speed (0.5 m/s) for a short distance (Fig. 7C,
Video 1). A single LB is frequently targeted by vesicles (Videos
1–3) and eventually returns to the LB cluster in a directed fast
movement (Fig. 7E, Video 3), apparently through interaction
with one or more microtubule-associated vesicles. We also ob-
serve interactions of vesicles with LBs with the vesicle appear-
ing as a light-intense spot moving on the surface of the LB and
eventually leaving it (Video 2). Vesicles with a lower velocity
(0.7 m/s) are transiently interacting with each other and
occasionally form couples or fuse to tubules. A vesicle couple
may separate, one staying in place and the other moving to-
ward a LB, interacting with it, and returning to its vesicle
partner (Fig. 7D, Video 2).
LB-associated Proteins—To identify possible stomatin-inter-
acting partners and to gain insight into LB composition, we
performed a proteomic study, the first on human LBs. We used
the human carcinoma A431 cells with very low endogenous
stomatin levels and A431 cells stably overexpressing WT sto-
matin. In the presence of oleic acid, the WT stomatin express-
ing A431 cells show stomatin targeting to small LBs, the
plasma membrane, and perinuclear region (Fig. 8A). In A431
cells, WT stomatin is not as effectively associated with LBs as
in MDCK cells; however, MDCK cells are currently unsuitable
for proteomic studies. LBs of A431 cells grown in oleic acid-
containing medium for 48 h were isolated by density gradient
centrifugation. Western blot analysis of the gradient fractions
shows the exclusive presence of the marker adipophilin/ADRP
in the LB fraction (Fig. 8B), demonstrating the efficiency of the
LB isolation procedure. When we compared the LB protein
bands from stomatin-positive and negative cells, we did not
detect a significant difference with the exception of the stoma-
tin band (data not shown). Fig. 8C shows the SDS-PAGE anal-
ysis of LBs from stomatin-expressing A431 cells and the results
of the MALDI-TOF-mass spectrometric analysis while details
on the identified proteins are given in Table I.
FIG. 7. Interaction of StomGFP-positive LBs with StomGFP-
positive vesicles and the microtubular network. A, MDCK cells
stably expressing StomGFP were treated with oleic acid for 24 h and
stained with anti-tubulin (red). There is no clear association of LBs with
microtubules, but negative staining of the LBs in the network is visible.
Thickened areas of StomGFP (arrowheads) and spike-like protrusions
from the LB rings are observed (inset, 2.5 magnification). Individual
StomGFP-positive vesicles are also visible (arrows). B, MDCK cells
stably expressing StomGFP were treated with oleic acid for 24 h fol-
lowed by nocodazole for 4 h. Microtubules are disrupted resulting in
diffuse cytoplasmic tubulin staining. The cellular distribution of LBs
appears unaffected, whereas StomGFP-positive vesicles form aggre-
gates (arrows). C–E, MDCK cells stably expressing StomGFP were
grown on a coverslip and subjected to Live microscopy. A set of six
planes in the z axis with exposure times of 10 ms/plane was taken every
490 ms using a Zeiss Axiovert 200 at a magnification of 100. From
three videos (Video 1, 2, and 3), three respective photoseries (C–E) were
selected showing just one plane at chosen time points as indicated. C, a
highly mobile LB (arrow) leaves a cluster, stops, and interacts with a
vesicle (arrowhead). Eventually, a vesicle returns to the LB cluster and
interacts with one of the LBs. D, two vesicles (arrowheads) interact with
each other and then dissociate for a short time during which one
interacts with an LB (arrow). Subsequently, the vesicles appear to fuse
and separate again. E, a highly mobile LB (arrow) is accompanied by
two vesicles to the left and right (arrowheads). The LB and the left
vesicle (arrowhead) move in concert toward an LB cluster, whereas the
right vesicle remains in place. Subsequently, an interaction with one
LB is observed. Bars  10 m (A and B) and 2 m (C–E).
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DISCUSSION
This study shows that either tagged or WT stomatin effi-
ciently associates with LBs when expressed in epithelial cells
grown in medium supplemented with oleic acid (Fig. 1). In
accordance with the current hypothesis of LB biogenesis (15)
and the reported association of caveolins with LBs (11–13), we
suggest that stomatin uses the same pathway of LB targeting,
namely synthesis at the cytoplasmic ER membrane and lateral
diffusion in the cytoplasmic leaflet to the nascent LBs where it
eventually buds off. Similar to the caveolins, it is apparently
the overexpression of stomatin that targets this protein to the
LBs. In other words, the transport of highly expressed caveo-
lins or stomatin to the LBs may represent an “overflow” path-
way from the ER (16). The formation of LBs and the co-local-
ization of endogenous stomatin additionally depend on the
availability of fatty acids. When epithelial cells are grown
under normal cell culture conditions, only few LBs can be
identified in these cells and the LBs do not co-localize with
endogenous stomatin. However, when the culture medium is
supplemented with a physiological concentration of oleic acid, a
small amount of stomatin associates with the newly formed
LBs (Fig. 2). Treatment of UAC epithelial cells with BFA to
collapse the Golgi apparatus into the ER (37) also leads to the
partial association of endogenous stomatin with small LBs that
is dramatically enhanced on supplementation with oleic acid
(Fig. 3C). Interestingly, even after a 17-h washout of the drug,
endogenous stomatin is still observed on LBs (Fig. 3D). This
finding is in marked contrast to the recovery of endogenous
caveolin from LBs that is almost complete after a 30–45-min
washout of BFA (14). However, overexpressed caveolin-1 is also
observed on LBs after BFA washout (12). The cause of the
increased affinity for LBs may be either a change in LB lipid
composition or a change in protein conformation.
Our data suggest that the long hydrophobic domain of stoma-
tin is necessary for the LB association as recently shown for
caveolin-1 (38), but neither the N nor the C terminus is required
(Fig. 4). This is an interesting finding, because we have previ-
ously shown that the C terminus is important for the oligomer-
ization and lipid raft association of stomatin (8). As stomatin
normally follows the Golgi-dependent pathway (39), we conclude
that the association of stomatin with either lipid rafts or LBs
involves different mechanisms in different compartments.
Stomatin and the caveolins normally show different subcel-
lular localizations. Although caveolins are located in caveolae
and the Golgi complex, stomatin is found at the plasma mem-
brane but not in caveolae and in the late endosomal/lysosomal
perinuclear region (8). It is therefore interesting to find
StomGFP and the LB-specific cav3-mutant DGV(cav3)HA ex-
pressed on the same LBs (Fig. 5). Both proteins appear to have
the intrinsic property to form domains on the LB surface. The
molecular mechanisms leading to this domain formation and
eventual diffusion remain unclear; however, the presence of the
StomGFP and DGV(cav3)HA-specific domains may indicate
that these proteins are targeted to different subcompartments
in the ER membrane (40). Our finding that the stomatin-
related protein flotillin-2/reggie-1 does not associate with LBs
but rather with the plasma membrane (Fig. 5D) is consistent
with the data showing that the homologous protein flotillin-1/
reggie-2 is sorted directly to the plasma membrane via a Golgi-
independent pathway (39). Probably, the lack of a large hydro-
phobic domain prevents the targeting of flotillins to the ER
membrane.
When cells overexpressing StomGFP on LBs are treated with
cycloheximide to block the protein synthesis, the LB associa-
tion of StomGFP is gradually lost and redistribution to small
perinuclear, acidic vesicles is observed (Fig. 6). These vesicles
are possibly targeted for degradation. Under the same condi-
tions, DGV(cav3)HA is also found to be absent from LBs and is
detected on large Nile red-negative vesicles (Fig. 6) as de-
FIG. 8. Identification of LB-associated proteins by proteomic
analysis. A, A431 cells stably expressing human WT stomatin were
treated with oleic acid for 24 h and stained with anti-stomatin and Nile
red. Arrows indicate small LBs surrounded by stomatin. Bar  10 m.
B and C, LBs from oleic-acid treated A431 cells stably expressing
stomatin were isolated by discontinuous density gradient centrifuga-
tion. B, aliquots of the density gradient fractions were analyzed by
Western blotting as indicated. C, isolated LBs were subjected to SDS-
PAGE and silver staining, the major bands were excised, the proteins
were digested, and the peptides were analyzed by MALDI-TOF
MS. PDI, protein-disulfide isomerase. LACS3, long-chain acyl-CoA
synthetase 3.
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TABLE I
Proteomic analysis of LB-associated proteins
LBs from oleic-acid-treated A431 cells stably expressing stomatin were isolated by discontinuous density gradient centrifugation and subjected
to SDS-PAGE and silver staining. The major bands were excised, the proteins were digested, and the peptides were analyzed by MALDI-TOF MS.
Abbreviations: PM, plasma membrane; PKC, protein kinase c; LPL, lipoprotein lipase; FAT, fatty acid translocase (CD36); H-FABP, heart-type
fatty acid-binding protein; ACS, acyl-CoA synthetase; LCAD, long-chain acyl-CoA dehydrogenase; BiP, luminal ER immunoglobulin-binding
protein; TGD, triglyceride droplets; PDI, protein-disulfide isomerase; AMID, apoptosis-inducing factor-homologous mitochondrion-associated
protein; CHILD syndrome, congenital hemidyplasia with ichthyosiform erythroderma and limb defects; LE, late endosomes; EE, early endosomes;
MHC, major histocompatibility complex; LACS 3, Long-chain acyl-CoA synthetase 3; GRP94, 94-kDa glucose-regulated protein, gp96 homolog;
TGN, trans-Golgi network; CGI, comparative gene identification.
Protein
GenBankTM
accession
number
Molecular mass MS
coverage RemarksTheoretical Observed
kDa %
Acetyl-coenzyme A carboxylase NP_000655 266.62 230 5 Enzyme for the first and rate-limiting step in fatty
acid synthesis
Protein kinase D2 NP_057541 98.04 115 18 PKD2 translocates from the cytoplasm to the PM
upon cell activation (requires PKC activity) (55)
GRP94 P14625 90.35 107 21 Chaperones peptides to MHC class I molecules of
dendritic cells and other antigen-presenting cells
(61)
HSP90- P07900 85.06 90 23 Chaperone; inhibition of function by ansamycins
causes the morphological and functional
differentiation (lipid bodies) of breast cancer cells
(62)
HSP90- P08238 83.3 90 25 Chaperone
Similar to villin 2 (ezrin) AAH13903 69.51 80 17 Cortical cytoskeleton component
Lanosterol synthase P48449 84.49 76 39 Yeast homologue Erg7p is a major component of LBs
(46)
LACS 3 O95573 81.37 76 25 In fasting BALB/c mice, VLDL receptor, LPL, FAT,
H-FABP, ACS, and LCAD expressions are
increased; LBs accumulate in the heart (63)
BiP P11021 71.03 74 21 Chaperone, found on purified TGD/LBs from murine
adipocytes together with calnexin (59)
HSC70 NP_006588 70.9 74 48 Chaperone
HSP60 P10809 61.05 65 16 Chaperonin
PDI NP_000909 57.5 62 20 Redox-chaperone, part of the heterodimeric
microsomal triglyceride transfer protein (64)
Transport-secretion protein 2.1 CAC01131 58.41 62 21 Similar to adiponutrin, which is linked to obesity
(54)
Squalene epoxidase AAD10823 63.9 60 33 Key enzyme of cholesterol biosynthesis; inhibition in
tellurium neuropathy leads to LBs in Schwann
cells (65). Yeast homologue Erg1p is a component
of LBs (45)
ADRP (adipophilin) Q99541 48.31 52 36 Adipose differentiation-related protein; LB-marker
(20, 27, 66)
Cytokeratin 8 P05787 53.66 51 29 Intermediate filament component
TIP47 O60664 47.19 48 60 47-kDa mannose 6-phosphate receptor-binding
protein; associates with LBs (20, 53)
Cytokeratin 18 P05783 48.04 47 40 Intermediate filament component
-actin AAH08633 41 44 40 Found on LBs of rat adrenocortical cells and
adipocytes (57)
CGI-58 protein NP_057090 39.04 44 36 Mutations in CGI-58 (esterase/lipase/ thioesterase
subfamily) in Chanarin-Dorfman syndrome lead to
accumulation of LBs in most tissues (47)
p53-responsive gene 3 (AMID) NP_116186 40.6 43 27 Induction of caspase-independent apoptosis (56)
NAD(P)-dependent steroid
dehydrogenase
Q15738 42.17 39 44 Found on the surface of mammalian LBs (44, 67).
CHILD syndrome fibroblasts from involved skin
accumulate cytoplasmic lipid (68).
NADH cytochrome b5 reductase P00387 34.45 34 47 Involved in desaturation and elongation of fatty
acids and in cholesterol biosynthesis; mnd/mnd
mutant mice accumulate LBs, and the enzyme
redistributes to ER (69)
17--Hydroxysteroid
dehydrogenase type VII
(17--HSD7)
P56937 38.2 32 21 Oxidizes or reduces estrogens and androgens in
mammals and regulates their biological potency
Retinal short-chain dehydrogenase/
reductase
(17--HSD11)
NP_057329 33.29 31 43 Retinylesters are the major lipids in LBs of stellate
cells of rat liver; major vitamin A reservoir (70)
Stomatin P27105 31.5 31 33 Found on LBs on overexpression (this study)
Tumor protein D54 O43399 22.2 30 77 Implicated in vesicle transport (52)
Rab1B Q9H0U4 22.3 23 47 Ras-related protein; involved in ER-Golgi transport
(48)
Calcium-binding protein p22 Q99653 22.44 23 61 Required for constitutive membrane traffic (51)
Rab6A P20340 23.69 20 53 Ras-related protein; retrograde Golgi-ER and intra-
Golgi transport (48)
Rab7 P51149 23.8 20 65 Mediates fusion of LE with each other and plays a
role in delivering cargo from EE to LE (48)
Rab10 O88386 22.75 20 39 Role in Golgi to TGN transport (48)
Rab18 NP_067075 23.24 13 49 Associated with EE and LE (48)
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scribed previously (13). Apparently, StomGFP and DGV-
(cav3)HA segregate from LBs to different vesicle populations. A
time course study of the StomGFP association with acidic ves-
icles shows that the redistribution is a slow process starting
after 3 h and completing after 24 h of cycloheximide treatment
(data not shown). The mechanism of StomGFP transfer to the
perinuclear region is not known; however, there are various
possibilities for StomGFP transport from the LBs. StomGFP
may be taken up by repeated vesicle interaction and targeting
to the perinuclear region, or the LBs may directly interact with
lysosomes. The core lipids may be hydrolyzed and transported,
and eventually, the residual small bodies may be targeted to
the perinuclear region. Indeed, we observed that several Lyso-
Tracker-positive yet StomGFP-negative vesicles are in close
contact with the ring-like StomGFP-positive LBs after a short
treatment with cycloheximide (data not shown). Alternatively,
we observed multiple interactions of LBs with vesicles that
could account for StomGFP transport (Fig. 7, C–E, Videos 1–3).
Live microscopy studies of StomGFP-positive LBs in three
dimensions revealed for the first time that LBs are dynamic
structures interacting with small StomGFP-positive cytoplas-
mic vesicles (Fig. 7, Videos 1–3). LBs often assemble in clusters
and exhibit little directed motion, but occasionally, single
StomGFP-positive LBs are observed that show transient mo-
tility (on average 0.5 m/s) in accordance with data from a
live cell analysis of GFP-ADRP-labeled LBs (66); however, the
reported motility of these LBs (2–2.5 m/s) is much higher. It is
known from a previous study that the movement of LBs de-
pends on microtubules (41). Apparently, the StomGFP-positive
small vesicles are also associated with microtubules, because
the addition of nocodazole leads to the loss of vesicle motility
(data not shown) and to vesicle aggregation (Fig. 7, A and B).
StomGFP-positive vesicles show fast, linear, and bidirectional
motion (Videos 1–3), but those eventually interacting with LBs
have a lower speed (0.7 m/s) and frequently stop. They also
interact with each other, apparently fuse, and separate again
(Fig. 7D, Video 2). These findings are consistent with previous
studies revealing a highly dynamic network of Rab7-positive
late endocytic vesicles that move at 0.5  0.2 m/s (42). The
motility of these vesicles depends on the membrane lipid com-
position in that they become immobile on cholesterol loading. It
remains to be investigated which kind of cargo is transported
by the StomGFP-positive vesicles and possibly exchanged with
the LBs.
The proteomic analysis of LB-associated proteins from hu-
man A431 cells (Fig. 8 and Table I) identified the marker
proteins adipophilin/ADRP and TIP47, several lipid metabolic
enzymes, Rab GTPases, transport-associated proteins, regula-
tory proteins, heat shock proteins, and cytoskeletal compo-
nents. Whereas adipophilin is a highly specific LB marker (17,
18), TIP47 was previously characterized as a cargo selection
protein required for the transport of the mannose 6-phosphate
receptors from late endosomes to the Golgi complex (43). Con-
sequently, a TIP47-dependent link between surface domains of
LBs and late endosomal sorting was recently proposed (44). In
accordance with the lipid storage and maintenance function,
we identified nine lipid metabolic enzymes, three of which were
previously found on yeast lipid particles: the lanosterol syn-
thase/Erg7p; squalene epoxidase/Erg1p; and long-chain fatty
acid CoA ligase/Faa4p (17, 45, 46). Acetyl-CoA carboxylase is
the key enzyme of fatty acid synthesis. NAD(P)-dependent
steroid dehydrogenase, 17--hydroxysteroid dehydrogenase 7
and 17--hydroxysteroid dehydrogenase 11 (retinal short-chain
dehydrogenase/reductase), and NADH cytochrome b5 reduc-
tase are involved in steroid synthesis or vitamin A homeostasis,
and CGI-58 is a putative lipase (47). Importantly, we identified
several Ras-related proteins, Rab1B, Rab6A, Rab7, Rab10, and
Rab18. These small GTPases participate in transport vesicle
formation, motility, docking, and fusion within the endocytic
and secretory pathways (48, 49). Multiple Rab proteins were
recently identified on LBs from Chinese hamster ovary cells
(50). The authors explain these data by envisaging the LB as a
“traffic hub or way station for multiple membrane pathways.”
This view is supported by our finding of proteins that are
involved in vesicle transport, p22 (51), tumor protein D54 (52),
TIP47 (20, 53), and transport-secretion protein 2.1 that is ho-
mologous to adiponutrin (54). Protein kinase D2 (55) and apo-
ptosis-inducing factor-homologous mitochondrion-associated
protein (56) are potential regulators for linking the cellular
metabolic state to apoptosis. Cytoskeletal proteins were de-
scribed previously as LB components (57), forming a cage
around LBs. Attachment sites of the filaments on the LB sur-
face or, alternatively, sites of lipolysis may be visible as spikes
(Fig. 7A). The identification of heat shock proteins has to be
evaluated critically, because these proteins are highly concen-
trated in the lumen of the ER and may leak out when cells are
disrupted for the LB isolation. However, several reports have
shown that chaperones are also present in the cytosol and play
an important role in protein folding and prevention of protein
aggregation (58). Luminal ER immunoglobulin-binding protein
was identified on the surface of LBs (59) and was found to
redistribute from the lumen to the cytosol upon ER stress (60),
thereby forming complexes with caspases to prevent ER stress-
induced apoptosis. Whether these chaperones associate with
LBs constitutively or after induction by stress signals has to
be investigated.
In conclusion, our study shows that stomatin, similar to the
caveolins, associates with LBs under certain conditions. The
proteins of both families have an unusual topology with one
long hydrophobic domain thought to be inserted in the mem-
brane by a hairpin loop flanked by partially membrane-associ-
ated cytoplasmic regions. This topology may confer the basis of
their affinity for lipid rafts and LBs. The function of stomatin is
not clear, but there are several options. As a raft protein, it
could bind and organize lipids either as an oligomeric scaffold-
ing protein or as an active signaling component involved in
cargo selection and vesicle trafficking as suggested by the in-
teraction of StomGFP-positive LBs with vesicles that may be
connected to the late endosomal compartment. Further studies
are necessary to reveal the nature of these vesicles and the role
of stomatin in vesicle formation, docking, fusion, and motility.
The emerging role of LBs as metabolically active organelles
opens up the possibility that stomatin may also be involved in
the regulation of metabolic pathways.
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